Stocks · News reference
Armata Pharmaceuticals shares are trading higher after the company announced it received FDA Breakthrough Therapy designation for AP-SA02.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Armata Pharmaceuticals shares are trading lower after the company announced the receipt of an additional $3.7 million in non-dilutive funds from the U.S. DoW for Phase 3 development program for AP-SA02.
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program
Armata Pharmaceuticals technical headwinds overshadow a $3.7 million Department of Defense grant funding its Phase 3 bacteriophage program.
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $15 price target.